The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases
Open accessAbstract
Bcl2 phosphorylation at Ser-70 may be required for the full and potent suppression of apoptosis in IL-3-dependent myeloid cells and can result from agonist activation of mitochondrial protein kinase C (PKC). Paradoxically, expression of exogenous Bcl2 can protect parental cells from apoptosis induced by the potent PKC inhibitor, staurosporine (stauro). High concentrations of stauro of up to 1 μM only partially inhibit IL-3-stimulated Bcl2 phosphorylation but completely block PKC-mediated Bcl2 phosphorylation in vitro . These data indicate a role for a stauro-resistant Bcl2 kinase (SRK). We show that aurintricarboxylic acid (ATA), a nonpeptide activator of cellular MEK/mitogen-activated protein kinase (MAPK) kinase, can induce Ser-70 phosphorylation of Bcl2 and support survival of cells expressing wild-type but not the phosphorylation-incompetent S70A mutant Bcl2. A role for a MEK/MAPK as a responsible SRK was implicated because the highly specific MEK/MAPK inhibitor, PD98059, also can only partially inhibit IL-3-induced Bcl2 phosphorylation, whereas the combination of PD98059 and stauro completely blocks phosphorylation and synergistically enhances apoptosis. p44MAPK/extracellular signal-regulated kinase 1 (ERK1) and p42 MAPK/ERK2 are activated by IL-3, colocalize with mitochondrial Bcl2, and can directly phosphorylate Bcl2 on Ser-70 in a stauro-resistant manner both in vitro and in vivo . These findings suggest a role for the ERK1/2 kinases as SRKs. Thus, the SRKs can serve to functionally link the IL-3-stimulated proliferative and survival signaling pathways and, in a novel capacity, may explain how Bcl2 can suppress stauro-induced apoptosis. In addition, although the mechanism of regulation of Bcl2 by phosphorylation is not yet clear, our results indicate that phosphorylation may functionally stabilize the Bcl2-Bax heterodimerization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death
Oltval, Z. N., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)90509-o · Cited by 6,003
Cited by
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Chang, F., Lehmann, B., Terrian, D. M., Milella, M., Tafuri, A., et al. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.10.001 · Cited by 2,284
BCL-2 family proteins: changing partners in the dance towards death
Kale, J., Osterlund, E. J., & Andrews, D. W. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.186 · Cited by 1,574
Konopleva, M., Contractor, R., Tsao, T., Samudio, I., Ruvolo, P. P., Kitada, S., Deng, X., Zhai, D., Shi, Y.-X., Sneed, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.006 · Cited by 1,023
Self-citationThe mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update
Siddiqui, W. A., Ahad, A., & Ahsan, H. (2015) · Archives of Toxicology · doi:10.1007/s00204-014-1448-7 · Cited by 696
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Abrams, S. L., Lee, J. T., Chang, F., Bertrand, F. E., Navolanic, P. M., Terrian, D. M., Franklin, R. A., D’Assoro, A. B., et al. (2006) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2006.01.004 · Cited by 664
Fernald, K., & Kurokawa, M. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.07.006 · Cited by 579
Mitochondria: The Next (Neurode)Generation
Schon, E. A., & Przedborski, S. (2011) · Neuron · doi:10.1016/j.neuron.2011.06.003 · Cited by 568
The ERK Cascade: Distinct Functions within Various Subcellular Organelles
Wortzel, I., & Seger, R. (2011) · Genes & Cancer · doi:10.1177/1947601911407328 · Cited by 563
Phosphorylation of Bcl2 and regulation of apoptosis
Ruvolo, P., Deng, X., & May, W. (2001) · Leukemia · doi:10.1038/sj.leu.2402090 · Cited by 504
Self-citationBaines, C. P., Zhang, J., Wang, G.-W., Zheng, Y.-T., Xiu, J. X., Cardwell, E. M., Bolli, R., & Ping, P. (2002) · Circulation Research · doi:10.1161/01.res.0000012702.90501.8d · Cited by 429
Targeting the ERK signaling pathway in cancer therapy
Kohno, M., & Pouyssegur, J. (2006) · Annals of Medicine · doi:10.1080/07853890600551037 · Cited by 416
Kalesnikoff, J., Huber, M., Lam, V., Damen, J. E., Zhang, J., Siraganian, R. P., & Krystal, G. (2001) · Immunity · doi:10.1016/s1074-7613(01)00159-5 · Cited by 412
Davies, B. R., Logie, A., McKay, J. S., Martin, P., Steele, S., Jenkins, R., Cockerill, M., Cartlidge, S., & Smith, P. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0231 · Cited by 387
Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia
Zhang, W., Konopleva, M., Shi, Y.-X., McQueen, T., Harris, D., Ling, X., Estrov, Z., Quintás-Cardama, A., Small, D., Cortes, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm328 · Cited by 338
Domina, A. M., Vrana, J. A., Gregory, M. A., Hann, S. R., & Craig, R. W. (2004) · Oncogene · doi:10.1038/sj.onc.1207692 · Cited by 327
“H7 (May et al., 1994; Ito et al., 1997; Deng et al., 2000).”
MethodTherapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia
Milella, M., Kornblau, S. M., Estrov, Z., Carter, B. Z., Lapillonne, H., Harris, D., Konopleva, M., Zhao, S., Estey, E., & Andreeff, M. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12807 · Cited by 312
Phosphorylation by Aurora B Converts MgcRacGAP to a RhoGAP during Cytokinesis
Minoshima, Y., Kawashima, T., Hirose, K., Tonozuka, Y., Kawajiri, A., Bao, Y. C., Deng, X., Tatsuka, M., Narumiya, S., May, W. S., et al. (2003) · Developmental Cell · doi:10.1016/s1534-5807(03)00089-3 · Cited by 310
Self-citationNovel Role for JNK as a Stress-activated Bcl2 Kinase
Deng, X., Xiao, L., Lang, W., Gao, F., Ruvolo, P., & May, W. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100279200 · Cited by 295
Self-citationDifferentiation therapy of human cancer: basic science and clinical applications
Leszczyniecka, M., Roberts, T., Dent, P., Grant, S., & Fisher, P. B. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00132-2 · Cited by 292
Pattingre, S., Bauvy, C., & Codogno, P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210998200 · Cited by 273
Bharadwaj, U., Marin-Muller, C., Li, M., Chen, C., & Yao, Q. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-106 · Cited by 151
“Phosphorylation of Bcl-2 at Ser70 is necessary for its anti-apoptotic function [41].”
BackgroundCrossing paths: interactions between the cell death machinery and growth factor survival signals
Brumatti, G., Salmanidis, M., & Ekert, P. G. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0288-8 · Cited by 85
“nalling [66–68].”
The protein kinase C (PKC) family of proteins in cytokine signaling in hematopoiesis
Redig, A. J., & Platanias, L. C. (2007) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2007.0007 · Cited by 51
“89 As with other growth factor pathways, the role of PKC isoforms in IL-3 signaling appears to be influenced by both cell type and the presence or absence of other complementary signaling elements.”
Metadata
- Authors
- Deng, X., Ruvolo, P., Carr, B., & May, W. S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-02-15
- Volume
- 97
- Issue
- 4
- Pages
- 1578-1583
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2127868048
- Cited by
- 247
- References
- 1
- FWCI
- 6.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.